Neuro and inflammation biotech Contineum Therapeutics sets terms for $150 million IPO

Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for IPF and multiple sclerosis, announced terms for its IPO on Monday.

The San Diego, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Contineum Therapeutics would command a fully diluted market value of $490 million.